Drug intelligence / Profile preview

MDX-2201

Development stage: Unknown
Lead developer: Merck
Modality: Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

MDX-2201 is a nanoparticle vaccine candidate designed to target the Epstein-Barr virus (EBV). Developed by ModeX Therapeutics, a subsidiary of OPKO Health, in collaboration with Merck & Co., the vaccine utilizes a multi-target nanoparticle platform to elicit immune responses against EBV. EBV is a ubiquitous human herpesvirus associated with infectious mononucleosis and several types of cancer, including nasopharyngeal carcinoma and certain lymphomas. The collaboration, established in March 2023, grants Merck an exclusive worldwide license for clinical development and commercialization. The vaccine program advanced into Phase 1 clinical trials in late 2024, aiming to address the significant unmet need for a preventative EBV vaccine.

Beyond the preview

Go deeper on MDX-2201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MDX-2201.

Explore the full profile